Skip to Content

Join the 'Pembrolizumab' group to help and get support from people like you.

Pembrolizumab News

Patients' Gut Bugs May Play Role in Cancer Care

Posted 3 Nov 2017 by Drugs.com

THURSDAY, Nov. 2, 2017 – The type of bacteria that cancer patients harbor in the gut might affect their odds of responding to certain treatments, two early studies hint. The research, in humans and mice, adds to evidence that gut bacteria play a key role in the immune system. But experts stressed it's too soon to make recommendations to cancer patients – including whether they should take ...

FDA Approves Merck’s Keytruda (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1

Posted 25 Sep 2017 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) September 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal j ...

FDA Medwatch Alert: Keytruda (pembrolizumab) in Patients with Multiple Myeloma: FDA Statement - Two Clinical Trials on Hold

Posted 1 Sep 2017 by Drugs.com

ISSUE: Based on data from two recently halted clinical trials, the U.S. Food and Drug Administration today is issuing this statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Experimental Gene-Targeted Drug Hits Cancer Where It Lives

Posted 4 Jun 2017 by Drugs.com

SATURDAY, June 3, 2017 – An experimental drug that targets a specific gene mutation can battle a range of advanced cancers in adults and children, researchers are reporting. The genetic abnormality is known as a TRK fusion, and it's found in only a small percentage of all cancers. So the drug, called larotrectinib, is no panacea. But researchers found that among 50 patients with TRK fusions, 76 ...

FDA Approves Keytruda (pembrolizumab) as First Cancer Treatment for any Solid Tumor with a Specific Genetic Feature

Posted 25 May 2017 by Drugs.com

May 23, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Keytruda (pembrolizumab) is indicated for the treatment of adult ...

FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL)

Posted 15 Mar 2017 by Drugs.com

KENILWORTH, N.J. March 14, 2017 --(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have r ...

Powerful Cancer Drugs Linked to Rare Heart Risks

Posted 3 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – In rare cases, potent drugs that prompt the immune system to fight cancer may threaten the heart in the process, researchers report. Known as immunotherapy, these medications have transformed cancer treatment in recent years, sending some patients who had few options left into remission. But a report in the Nov. 3 issue of New England Journal of Medicine describes two ...

FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Posted 25 Oct 2016 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) October 24, 2016 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have ...

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of ...

FDA Approves Merck’s Keytruda (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Posted 8 Aug 2016 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE)--August 5, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or metastatic head and ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

'Precision' Cancer Treatment May Extend Lives

Posted 20 May 2016 by Drugs.com

THURSDAY, May 19, 2016 – "Precision" cancer treatment that's guided by genetic clues from the patient's own tumor appears to outperform traditional chemotherapy, a new research review finds. Patients given precision – or personalized – treatment experienced a tumor shrinkage rate six times that attained by regular chemotherapy. But, that only happened if doctors used genetic information to ...

FDA Approves Expanded Indication for Keytruda (pembrolizumab) for the Treatment of Patients with Advanced Melanoma

Posted 23 Dec 2015 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) December 18, 2015 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic m ...

Keytruda Approved for Leading Form of Lung Cancer

Posted 2 Oct 2015 by Drugs.com

FRIDAY, Oct. 2, 2015 – Keytruda (pembrolizumab) has been approved by the U.S. Food and Drug Administration to treat advanced cases of the most common type of lung malignancy, non-small cell lung cancer (NSCLC). The drug is approved for people whose tumors produce a protein called PD-L1, and whose cancer has lingered despite use of other treatments, the agency said Friday in a news release. Lung ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma - Metastatic, Solid Tumors, Colorectal Cancer, Hodgkin's Lymphoma, Urothelial Carcinoma, Melanoma, Gastric Cancer

Related Drug Support Groups

Keytruda

Pembrolizumab Patient Information at Drugs.com